The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...
ZME Science on MSN
People Taking Ozempic Say Booze Just Doesn’t Hit the Same and Now Scientists Know Why
At first glance, Ozempic and Wegovy seem like miracle drugs of the 21st century — a pair of injections that shrink waistlines ...
Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health ...
Marketing and manufacturing practices for compounded GLP-1RA drugs have come under FDA scrutiny, prompting policy changes.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention recently, both in the media and in ...
A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs. An alarming 40% of orders for glucagon-like peptide-1 ...
Pharmaceutical Technology on MSN
Kailera nets $600m to power Phase III launch of obesity drug
Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another ...
GLP-1RA use was associated with a lower risk for delirium within 5 years of use but a higher risk for delirium within 5 to 10 years of use among patients with type 2 diabetes. Delirium risk initially ...
Compared with nonuse, GLP-1RA and thiazolidinedione combination therapy reduced risks for all-cause and cardiovascular mortality in type 2 diabetes. The combination of a glucagon-like peptide 1 ...
In this cohort study, 40% of orders for glucagon-like peptide-1 receptor agonists (GLP-1RAs) were not filled. Non-Hispanic Black patients and Hispanic patients were less likely to fill orders than non ...
USA: A new study published in Arthritis & Rheumatology found that patients with lupus and type 2 diabetes, including those ...
PATIENTS with systemic lupus erythematosus (SLE) and Type 2 diabetes (T2D) had significantly lower cardiovascular, kidney, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results